2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-133119
    PK150 2165324-62-7 99.43%
    PK150, an analogue of Sorafenib, shows oral bioavailability and antibacterial activity against several pathogenic strains at submicromolar concentrations. PK150 inhibits Gram-positive Methicillin-sensitive S. aureus (MSSA), Methicillin-resistant S. aureus (MRSA), Vancomycin intermediate S. aureus (VISA) with MICs of 0.3, 0.3-1, 0.3 μM, respectively.
    PK150
  • HY-144645
    SP-471P 2768011-36-3 99.46%
    SP-471P is a potent dengue virus (DENV) protease inhibitor with EC50s of 5.9 μM, 1.4 μM, 5.1 μM and 1.7 μM for DENV1, DENV2, DENV3 and DENV4, respectively and CC50 value over 100 μM. SP-471P can reduce DENV viral RNA synthesis.
    SP-471P
  • HY-W003467
    Rabeprazole Sulfide 117977-21-6 98.09%
    Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion through an interaction with (H+/K+)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of H. pylori. Rabeprazole has the potential for various peptic diseases treatment.
    Rabeprazole Sulfide
  • HY-14926
    Levonadifloxacin 154357-42-3 99.79%
    Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes.
    Levonadifloxacin
  • HY-10574A
    Rilpivirine hydrochloride 700361-47-3 99.81%
    Rilpivirine (R278474) hydrochloride is a potent and specific diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI). Rilpivirine hydrochloride has high antiviral activity against wild-type HIV (EC50=0.4 nM) and mutant viruses (EC50=0.1-2.0 nM). Rilpivirine hydrochloride has a high genetic barrier to resistance development of HIV.
    Rilpivirine hydrochloride
  • HY-109014
    Tenofovir exalidex 911208-73-6 99.82%
    Tenofovir exalidex (CMX157) is a lipid conjugate of the acyclic nucleotide analog Tenofovir with activity against both wild-type and antiretroviral drug-resistant HIV strains, including multidrug nucleoside/nucleotide analog-resistant viruses. Tenofovir exalidex is active against all major subtypes of HIV-1 and HIV-2 in fresh human PBMCs and against all HIV-1 strains evaluated in monocyte-derived macrophages, with EC50s ranging between 0.2 and 7.2 nM. CMX157 is orally available and has no apparent toxicity. Tenofovir exalidex also shows antiviral activity against HBV.
    Tenofovir exalidex
  • HY-131350
    LXE408 1799330-15-6 99.08%
    LXE408 is an orally active, non-competitive and kinetoplastid-selective proteasome inhibitor. LXE408 has an IC50 of 0.04 μM for L. donovani proteasome and an EC50 of 0.04 μM for L. donovani. LXE408 has a low propensity to cross the blood brain barrier. LXE408 has the potential for visceral leishmaniasis (VL) research.
    LXE408
  • HY-132987
    Avibactam tomilopil 2245880-46-8 98.57%
    Avibactam tomilopil (ARX-1796, AV-006) is an orally active prodrug of Avibactam and a β-lactamase inhibitor. Avibactam tomilopil can be used in the study of diseases such as urinary tract infections.
    Avibactam tomilopil
  • HY-139398
    TBI-223 2071265-08-0 99.73%
    TBI-223 is an orally bioavailable oxazolidinone antibiotic and an antimicrobial. TBI-223 shows activity against Mycobacterium tuberculosis (Mtb).
    TBI-223
  • HY-14648G
    Dexamethasone (GMP) 50-02-2 98%
    Dexamethasone (Hexadecadrol) (GMP) is Dexamethasone (HY-14648) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Dexamethasone is an agonist of glucocorticoid receptor.
    Dexamethasone (GMP)
  • HY-147358
    Yimitasvir diphosphate 1959593-63-5 98.09%
    Yimitasvir (Emitasvir) diphosphate is an orally active hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor and can be used for research of chronic hepatitis C virus infection.
    Yimitasvir diphosphate
  • HY-147411
    Ulonivirine 1591823-76-5 98.31%
    Ulonivirine (MK-8507) is an orally active non-nucleoside reverse transcriptase inhibitor with high antiviral activity. Ulonivirine can be used for the research of HIV-1 infection.
    Ulonivirine
  • HY-148797
    Rolusafine 2089153-78-4 98.78%
    Rolusafine is an antifungal agent.
    Rolusafine
  • HY-B0277A
    Vidarabine phosphate 29984-33-6 98.74%
    Vidarabine phosphate (Ara-AMP), an antiviral agent, inhibits chronic HBV infection. Vidarabine phosphate also against herpes simplex and varicella zoster viruses.
    Vidarabine phosphate
  • HY-P99346
    Regdanvimab 2444308-95-4
    Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19.
    Regdanvimab
  • HY-P99435
    Amubarvimab 2509447-07-6
    Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants.
    Amubarvimab
  • HY-U00160
    SP187 615253-61-7 ≥98.0%
    SP187 is a host-targeted iminosugar with activity against filovirus infections in vitro and in vivo. SP187 is active against influenza and dengue in vivo.
    SP187
  • HY-106574A
    Ceftobiprole medocaril sodium 252188-71-9
    Ceftobiprole medocaril (BAL5788) sodium is the parenteral proagent of Ceftobiprole (HY-112579). Ceftobiprole is a parenteral pyrrolidinone cephalosporin. Ceftobiprole is a broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- (MRSA) and vancomycin-resistant staphylococci (VRSA) and penicillin-resistant streptococci. Ceftobiprole also inhibits gram-positive and gram-negative pathogens.
    Ceftobiprole medocaril sodium
  • HY-123475A
    Sisunatovir hydrochloride 1903763-83-6 98.61%
    Sisunatovir (RV521) hydrochloride is a potent and orally active respiratory syncytial virus (RSV) inhibitor with IC50 values of 1.4, 1.0 nM for RSV A, RSV B, respectively. Sisunatovir hydrochloride inhibits RSV infection and reduces virus titers in the lungs of mice.
    Sisunatovir hydrochloride
  • HY-145569A
    Fipravirimat dihydrochloride 2442512-14-1 98%
    Fipravirimat dihydrochloride is a potent HIV-1 inhibitor. Fipravirimat dihydrochloride has the potential for HIV and AIDS research.
    Fipravirimat dihydrochloride
Cat. No. Product Name / Synonyms Application Reactivity